| related words |
| denied |
| predictive |
| elesclomol |
| zyflo |
| hemopure |
| endpoint |
| rigorous |
| nx |
| exacting |
| mistake |
| biovaxid |
| pivotal |
| investigator |
| xr |
| protocol |
| melanoma |
| submit |
| faropenem |
| assist |
| diabetes |
|
| related documents |
| 1003124--2/26/2010--PHARMACEUTICAL_PRODUCT_DEVELOPMENT_INC |
| 1412067--5/6/2010--Oncothyreon_Inc. |
| 1178879--3/10/2010--AMICUS_THERAPEUTICS_INC |
| 1157408--9/26/2008--K12_INC |
| 1441848--2/24/2010--FACET_BIOTECH_CORP |
| 1178879--2/8/2008--AMICUS_THERAPEUTICS_INC |
| 1171662--3/20/2007--TRIPLE-S_MANAGEMENT_CORP |
| 1005201--3/9/2010--DEPOMED_INC |
| 1099414--3/16/2007--TANOX_INC |
| 1142596--3/15/2007--NUVASIVE_INC |
| 1171662--3/5/2010--TRIPLE-S_MANAGEMENT_CORP |
| 1051514--3/15/2007--ELECTRO_OPTICAL_SCIENCES_INC_/NY |
| 1005201--3/16/2007--DEPOMED_INC |
| 1412067--3/30/2009--Oncothyreon_Inc. |
| 1114529--3/31/2006--VIACELL_INC |
| 1061027--3/30/2006--SUNESIS_PHARMACEUTICALS_INC |
| 1344154--2/23/2009--Emergency_Medical_Services_CORP |
| 1005201--3/6/2009--DEPOMED_INC |
| 1088856--3/31/2009--CORCEPT_THERAPEUTICS_INC |
| 1061027--3/17/2008--SUNESIS_PHARMACEUTICALS_INC |
|
| related topics |
| {product, candidate, development} |
| {regulation, government, change} |
| {system, service, information} |
| {cost, contract, operation} |
| {financial, litigation, operation} |
| {competitive, industry, competition} |
| {control, financial, internal} |
| {loss, insurance, financial} |
| {provision, law, control} |
| {interest, director, officer} |
| {condition, economic, financial} |
| {acquisition, growth, future} |
| {cost, operation, labor} |
| {investment, property, distribution} |
| {debt, indebtedness, cash} |
| {capital, credit, financial} |
| {operation, natural, condition} |
| {cost, regulation, environmental} |
| {customer, product, revenue} |
| {tax, income, asset} |
|